{"title":"Concomitant detection of serum ATF4 levels and MAGE is helpful to predict the occurrence of osteoporosis in patients with type 2 diabetes mellitus.","authors":"Jing Zhang, Wei Huang","doi":"10.1016/j.jcjd.2024.11.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Activating transcription factor 4 (ATF4) and mean amplitude of glycemic excursion (MAGE) have been implicated in the pathogenesis of osteoporosis (OP) and type 2 diabetes mellitus (T2DM). This retrospective cohort study assessed the predictive value of serum ATF4 and MAGE for the occurrence of OP in T2DM patients.</p><p><strong>Methods: </strong>A total of 162 patients with T2DM were assigned to T2DM and T2DM + OP groups. All participants underwent serum ATF4 level detection and 72-h blood glucose monitoring (MAGE measurement). The correlations of ATF4 and MAGE with glucose and bone metabolism indicators and bone mineral density (BMD) were analyzed. A multivariate logistic regression model was developed to evaluate the correlations of ATF4 and MAGE with T2DM-associated OP. The diagnostic performance of concomitant detection of ATF4 and MAGE was assessed based on the area under the receiver-operating characteristics curve (AUC).</p><p><strong>Results: </strong>T2DM patients with OP had higher serum ATF4 levels and MAGE than T2DM patients. ATF4 and MAGE were correlated positively with FINS, HbA1c, HOMA-IR, β-CTX, and TRACP-5b and negatively with BALP, PINP, PICP, and BMD. Elevated levels of ATF4 and MAGE were independent risk factors but increased BMD at the hip, femoral neck, and lumbar spine was a protective factor for T2DM patients with OP. More importantly, the AUC of concomitant ATF4 and MAGE was considerably higher than that of ATF4 or MAGE alone.</p><p><strong>Conclusion: </strong>Concomitant detection of ATF4 and MAGE potentially aids in predicting the occurrence of OP in patients with T2DM.</p>","PeriodicalId":93918,"journal":{"name":"Canadian journal of diabetes","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jcjd.2024.11.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Activating transcription factor 4 (ATF4) and mean amplitude of glycemic excursion (MAGE) have been implicated in the pathogenesis of osteoporosis (OP) and type 2 diabetes mellitus (T2DM). This retrospective cohort study assessed the predictive value of serum ATF4 and MAGE for the occurrence of OP in T2DM patients.
Methods: A total of 162 patients with T2DM were assigned to T2DM and T2DM + OP groups. All participants underwent serum ATF4 level detection and 72-h blood glucose monitoring (MAGE measurement). The correlations of ATF4 and MAGE with glucose and bone metabolism indicators and bone mineral density (BMD) were analyzed. A multivariate logistic regression model was developed to evaluate the correlations of ATF4 and MAGE with T2DM-associated OP. The diagnostic performance of concomitant detection of ATF4 and MAGE was assessed based on the area under the receiver-operating characteristics curve (AUC).
Results: T2DM patients with OP had higher serum ATF4 levels and MAGE than T2DM patients. ATF4 and MAGE were correlated positively with FINS, HbA1c, HOMA-IR, β-CTX, and TRACP-5b and negatively with BALP, PINP, PICP, and BMD. Elevated levels of ATF4 and MAGE were independent risk factors but increased BMD at the hip, femoral neck, and lumbar spine was a protective factor for T2DM patients with OP. More importantly, the AUC of concomitant ATF4 and MAGE was considerably higher than that of ATF4 or MAGE alone.
Conclusion: Concomitant detection of ATF4 and MAGE potentially aids in predicting the occurrence of OP in patients with T2DM.